SEVENFACT
The FDA has authorized SEVENFACT for the treatment and control of bleeding episodes in adults and adolescents aged 12 years and older who have hemophilia A or B with inhibitors.
Manufacturers of coagulation factor products and clinical teams managing hemophilia patients with inhibitors in the adolescent and adult demographic.
This update defines a specific therapeutic indication for a recombinant coagulation factor in a high-need patient population. The age-based restriction (12+) indicates that safety or efficacy data may be limited or insufficient for younger pediatric populations at this time, necessitating precise messaging in regulatory filings and clinical protocols.
Regulatory and clinical teams should verify that all labeling and promotional materials strictly align with the indicated age range (12 years and older) and patient population (Hemophilia A/B with inhibitors). Pharmacovigilance protocols should be updated to monitor safety signals within this specific demographic.
Treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors
Open in openFDA / FDA.gov